Antigenics, Inc. (NASDAQ:AGEN)

CAPS Rating: 2 out of 5

A biotechnology company, developing technologies and products to treat cancers and infectious diseases, based on immunological approaches.

Recs

1
Player Avatar Ernbo6 (58.56) Submitted: 5/15/2007 1:43:13 PM : Underperform Start Price: $18.48 AGEN Score: +116.77

Antigenics Inc. is a biotechnology company developing technologies and products to treat cancers, infectious diseases and autoimmune disorders, primarily based on immunological approaches. Its advanced product candidate is Oncophage (vitespen, formerly HSPPC-96), a personalized therapeutic cancer vaccine candidate being tested for several cancer indications. The Company's product candidate portfolio includes Oncophage (vitespen; formerly HSPPC-96), a personalized therapeutic cancer vaccine candidate that has been tested, or is being tested, in several cancer indications, including in Phase III clinical trials for the treatment of renal cell carcinoma and for metastatic melanoma. Oncophage is also being tested in Phase II and Phase I clinical trials in a range of indications
Put this on a watchlist...keep looking for the updates since this can be another Dendreon.

Member Avatar zzlangerhans (99.73) Submitted: 1/6/2011 2:52:03 AM
Recs: 0

Wrong way thumb garners high score and top pitch honors! Stopped clock proven to be correct twice a day!

Featured Broker Partners


Advertisement